Amg 162

Breast Cancer

AmgenPhase 3Dormant

CCC

52/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 59/ 100

Competitive context

891 Active assets in the Breast Cancer cohort.

Asset / Sponsor	Phase	Rating
Lapatinib University of New Mexico	Phase 3	BBB
Darolutamide Vandana Abramson	Phase 2	BBB
Trastuzumab Duocarmazine Byondis B.V.	Phase 3	BB
ERIBULIN MONOMETHANESULFONATE Henan Cancer Hospital	Phase 4	BB
Palbociclib Hoffmann-La Roche	Phase 4	BB

View all 50 →

Same molecule, other indications

Amg 162 is also rated in:

Bone Metastases in Subjects With Advanced Breast CancerDormant

BB

Indicative ·

69 / 100

OsteopeniaDormant

BB

Indicative ·

64 / 100

prostate cancerDormant

NR

Indicative ·

/ 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.